MiMedx Group (NASDAQ:MDXG) Stock Price Down 8.8% – Here’s What Happened

MiMedx Group, Inc (NASDAQ:MDXG)’s share price fell 8.8% during trading on Thursday . The company traded as low as $4.96 and last traded at $4.8160. 508,892 shares were traded during trading, a decline of 46% from the average session volume of 945,096 shares. The stock had previously closed at $5.28.

Key Headlines Impacting MiMedx Group

Here are the key news stories impacting MiMedx Group this week:

• Positive Sentiment: Q4 2025 results beat expectations — MiMedx reported $0.14 EPS vs. a $0.09 consensus and revenue of $118.1M vs. ~$106.8M expected, with improved margins and 27% ROE, supporting profitability progress. Q4 beat article
• Positive Sentiment: Company reported record Q4 and full‑year operating results and adjusted EBITDA of $29M (25% of net sales); management also authorized a $100M share repurchase program — a tangible capital-return action that can support the stock. Press release
• Neutral Sentiment: Management hosted an earnings call and published transcripts providing more color on surgical growth initiatives and reimbursement headwinds; these details will matter for modeling conversion of demand and margin sustainability. Earnings call transcript
• Neutral Sentiment: Analyst attention increased with coverage initiation from Citizens/JMP, which can boost liquidity and investor focus but not immediately change fundamentals. Coverage article
• Neutral Sentiment: Expanded public record of the call and earnings (transcripts and Yahoo/MarketBeat recaps) gives investors more primary material to re‑assess guidance assumptions. Call transcript
• Negative Sentiment: 2026 revenue guidance of $340M–$360M was below the consensus (~$375M), raising concerns that growth could decelerate due to reimbursement changes and slower near‑term adoption; that guidance miss likely drove the stock downward. Guidance article

Analyst Upgrades and Downgrades

Several research analysts have recently commented on MDXG shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of MiMedx Group in a research note on Monday, December 29th. UBS Group set a $10.00 price target on shares of MiMedx Group in a report on Monday. Citigroup assumed coverage on shares of MiMedx Group in a research note on Monday. They issued a “market outperform” rating for the company. Wall Street Zen upgraded MiMedx Group from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 2nd. Finally, Cantor Fitzgerald cut their price objective on shares of MiMedx Group from $12.00 to $8.00 and set an “overweight” rating for the company in a report on Tuesday, February 17th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, MiMedx Group has a consensus rating of “Moderate Buy” and an average target price of $9.60.

MiMedx Group Stock Down 6.3%

The firm has a market cap of $732.35 million, a P/E ratio of 18.28 and a beta of 1.59. The company has a current ratio of 4.41, a quick ratio of 3.95 and a debt-to-equity ratio of 0.07. The business has a 50-day moving average price of $5.78 and a 200-day moving average price of $6.60.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings results on Wednesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.05. MiMedx Group had a return on equity of 27.19% and a net margin of 10.38%.The business had revenue of $118.10 million for the quarter, compared to the consensus estimate of $106.78 million. On average, equities analysts forecast that MiMedx Group, Inc will post 0.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. First Light Asset Management LLC increased its stake in shares of MiMedx Group by 89.5% in the third quarter. First Light Asset Management LLC now owns 3,652,952 shares of the company’s stock worth $25,498,000 after acquiring an additional 1,725,458 shares during the period. Nantahala Capital Management LLC purchased a new stake in MiMedx Group in the third quarter valued at $10,237,000. Marshall Wace LLP grew its position in MiMedx Group by 864.9% during the 4th quarter. Marshall Wace LLP now owns 1,381,288 shares of the company’s stock worth $9,351,000 after purchasing an additional 1,238,132 shares during the period. Hillsdale Investment Management Inc. purchased a new position in shares of MiMedx Group during the 4th quarter valued at about $7,134,000. Finally, Disciplined Growth Investors Inc. MN raised its stake in shares of MiMedx Group by 283.0% during the 3rd quarter. Disciplined Growth Investors Inc. MN now owns 1,383,451 shares of the company’s stock valued at $9,656,000 after buying an additional 1,022,202 shares during the last quarter. 79.15% of the stock is owned by institutional investors and hedge funds.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.